Get the Stockscreener App
6.57
6.41%
-0.45
After Hours:
6.52
-0.05
-0.76%
Edesa Biotech Inc stock is traded at $6.57, with a volume of 520.03K.
It is down -6.41% in the last 24 hours and up +383.09% over the past month.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
See More
Previous Close:
$7.02
Open:
$6.76
24h Volume:
520.03K
Relative Volume:
0.13
Market Cap:
$54.85M
Revenue:
-
Net Income/Loss:
$-7.82M
P/E Ratio:
-5.7305
EPS:
-1.1465
Net Cash Flow:
$-8.00M
1W Performance:
-14.56%
1M Performance:
+383.09%
6M Performance:
+169.26%
1Y Performance:
+163.86%
1-Day Range:
$6.12
$6.95
1-Week Range:
$6.12
$9.37
52-Week Range:
$0.72
$9.37
Edesa Biotech Inc Stock (EDSA) Company Profile
Name
Edesa Biotech Inc
Sector
Industry
Phone
(905) 475-1234
Address
100 SPY COURT, MARKHAM, ON
Compare EDSA vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
6.57 | 58.60M | 0 | -7.82M | -8.00M | -1.1465 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Edesa Biotech Inc Stock (EDSA) Latest News
Gainers Report: Can Edesa Biotech Inc be the next market leader2026 Risk Factors & AI Powered Trade Plan Recommendations - baoquankhu1.vn
If You Invested $1,000 in Edesa Biotech Inc (EDSA) - Stock Titan
Edesa Biotech Inc. (EDSA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PERCEPTIVE ADVISORS LLC Acquires Significant Stake in Edesa Biotech Inc - GuruFocus
Volume Recap: Will Edesa Biotech Inc announce a stock split2026 Top Gainers & Weekly High Return Forecasts - baoquankhu1.vn
Bull Bear: Will Edesa Biotech Inc announce a stock splitPortfolio Gains Report & Daily Growth Stock Tips - baoquankhu1.vn
Perceptive Advisors stake: 563,239 shares in EDESA (NASDAQ: EDSA) - Stock Titan
EDSA SEC FilingsEdesa Biotech Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Edesa Biotech (EDSA) president buys 2,000 shares in open market - Stock Titan
Short Interest in Edesa Biotech, Inc. (NASDAQ:EDSA) Expands By 9,253.7% - MarketBeat
Edesa Biotech (EDSA) CEO adds 1,000 shares in open-market buy - Stock Titan
Best Biotech Stocks To Follow Today – March 7th - Defense World
Edesa Biotech’s Paridiprubart Trial Success Spurs Market Optimism - StocksToTrade
Edesa Biotech Gains Ground with Positive Clinical and Financial News - timothysykes.com
Will Edesa Biotech Inc. stock attract more institutional investorsPortfolio Performance Report & Weekly Return Optimization Plans - Naître et grandir
Best Biotech Stocks To Follow TodayMarch 7th - MarketBeat
Edesa Biotech Surges Following Promising Clinical Data in ARDS Treatment - StocksToTrade
Edesa Biotech Advances on Promising Drug Trial Results - timothysykes.com
Velan Capital Investment Management LP Increases Stake in Edesa Biotech Inc - GuruFocus
Edesa Biotech reports FQ1 net loss of $2.2 million - MSN
Price Action: Will Edesa Biotech Inc announce a stock splitJuly 2025 Earnings & High Yield Equity Trading Tips - baoquankhu1.vn
Edesa Biotech (NASDAQ:EDSA) CEO Pardeep Nijhawan Acquires 10,000 Shares - MarketBeat
Edesa Biotech (EDSA) CEO-linked entity adds 10,000 shares in open-market buy - Stock Titan
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Aug Mood: Can Edesa Biotech Inc be the next market leaderWatch List & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Edesa Biotech (EDSA) CEO-linked entity acquires 10,000 common shares - Stock Titan
FY2026 EPS Forecast for Edesa Biotech Decreased by Analyst - Defense World
CEO-linked entity buys 10,000 Edesa Biotech (EDSA) shares - Stock Titan
Edesa Biotech (NASDAQ: EDSA) CEO adds 3,000 shares in open-market purchases - Stock Titan
Point72 group (NASDAQ: EDSA) reports 600,000 shares, 7.2% stake - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Velan Capital details Edesa Biotech (NASDAQ: EDSA) 9.99% stake - Stock Titan
Nijhawan group boosts Edesa Biotech (EDSA) stake to 19.99% in 13D/A - Stock Titan
Edesa Biotech (NASDAQ: EDSA) CEO adds 50,571 shares in open-market buys - Stock Titan
[Form 4] Edesa Biotech, Inc. Insider Trading Activity - Stock Titan
EDSA: Strengthened Phase 3 ARDS Data Shows Significant Reduction in 28-Day Mortality - Research Tree
Edesa Biotech CEO Makes Bold Insider Move With Fresh Share Purchase - TipRanks
Edesa Biotech Advances with Promising Phase 3 Outcomes - StocksToTrade
Edesa Biotech’s Paridiprubart Phase 3 Success Drives Optimism - timothysykes.com
Edesa Biotech’s Strategic Advances Boost Stock Outlook - StocksToTrade
Edesa Biotech Surpasses Expectations with Promising Phase 3 Data - timothysykes.com
EDSA Technical Analysis & ETF Price Forecast - Intellectia AI
Why Is Edesa Biotech, Inc. (EDSA) Stock Up Today? - Meyka
Why Did EDSA Stock Rally More Than 70% Today? - Asianet Newsable
Biotech Stock Edesa Biotech (Nasdaq:EDSA) Gains on News of Additional Positive Results from Phase 3 Paridiprubart Study - Investorideas.com
Edesa Biotech stock surges on positive Phase 3 trial data By Investing.com - Investing.com Canada
Edesa Biotech stock surges on positive Phase 3 trial data - Investing.com
Edesa Biotech reports mortality reduction in phase 3 trial By Investing.com - Investing.com Australia
Edesa Biotech Reports Positive Phase 3 Paridiprubart Results - TipRanks
Edesa Biotech reports mortality reduction in phase 3 trial - Investing.com
Edesa Biotech reports additional results from phase 3 paridiprubart study - marketscreener.com
Edesa Biotech Inc Stock (EDSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):